SMS Pharmaceuticals Q2 Results FY27: Net Profit Jumps 57.45% to Rs 39.85 Cr, Revenue Rs 316.09 Cr

SMS Pharmaceuticals Ltd (SMSPHARMA) Q2 Results FY27 announced on 4 November 2026, covering the company's financial performance for the July to September quarter. The results date brought Consolidated revenue of Rs 316.09 Cr and PAT of Rs 39.85 Cr, and SMS Pharmaceuticals Q2 Results FY27 are read here on a consolidated results basis against the same quarter last year.

The results analysis of SMS Pharmaceuticals Q2 Results covers the financial highlights, the business factors, the outlook and the risks, with every figure taken from the declared filing. The Financial Highlights table below sets out revenue, Operating Profit and net profit against the same quarter last year.

Click Here – Get Free Investment Predictions

SMS Pharmaceuticals Q2 Results FY27: Financial Highlights

Metric	Q2 FY27 (Sep 26)	Q2 FY26 (Sep 25)	YoY Change
Revenue	Rs 316.09 Cr	Rs 242.43 Cr	+30.38% YoY
Operating Profit	Rs 67.66 Cr	Rs 48.36 Cr	+39.91% YoY
Net Profit (PAT)	Rs 39.85 Cr	Rs 25.31 Cr	+57.45% YoY

Source: company filing for SMS Pharmaceuticals Q2 Results FY27, 4 November 2026. Figures in Rs Crore, Consolidated basis.

Key Takeaways from SMS Pharmaceuticals Q2 Results: What Stands Out

• Revenue rose 30.38% YoY to Rs 316.09 Cr from Rs 242.43 Cr, a YoY growth figure that anchors SMS Pharmaceuticals Q2 Results FY27 on the top line.
• Net profit rose 57.45% to Rs 39.85 Cr from Rs 25.31 Cr, so net profit grew faster than revenue this quarter.
• Operating Profit rose 39.91% to Rs 67.66 Cr from Rs 48.36 Cr, a gain that sits between the revenue and net profit moves.
• Net profit margin improved to 12.6% from 10.4% in the comparison quarter, which shows more profit retained from each rupee of revenue.
• Quarterly revenue has swung between Rs 206.97 Cr and Rs 316.09 Cr over the last 5 quarters, a point covered in the risks section.
• Next comes the performance analysis, which places the revenue, Operating Profit and net profit moves side by side.

SMS Pharmaceuticals Q2 Results FY27: Performance Analysis

The numbers in SMS Pharmaceuticals Q2 Results FY27 show growth on every reported line. Consolidated revenue rose 30.38% YoY to Rs 316.09 Cr, Operating Profit rose 39.91% to Rs 67.66 Cr, and net profit rose 57.45% to Rs 39.85 Cr from Rs 25.31 Cr. That pattern is the central point of this results analysis.

In SMS Pharmaceuticals Q2 Results, revenue added Rs 73.66 Cr over the Rs 242.43 Cr of the same quarter last year, which is the YoY growth of 30.38%. Operating Profit added Rs 19.30 Cr over Rs 48.36 Cr. Alongside this, net profit added Rs 14.54 Cr, so the quarterly results show profit growing faster than revenue.

Net profit as a share of revenue improved to 12.6% from 10.4%, and the FY27 reading of SMS Pharmaceuticals Q2 Results FY27 will depend on whether revenue holds at this level in later quarters. Readers can compare the next declarations on the Univest Screener. This is where the results analysis turns to the business factors.

Check the Univest Screener for live results data

Key Business Factors This Quarter

Revenue Growth – The results analysis points to three business factors, and the first is revenue, which grew 30.4% year on year to Rs 316.09 Cr in the latest quarter, as recorded in SMS Pharmaceuticals Q2 Results FY27.

Net Profit Rise – Net profit rose 57.4% year on year to Rs 39.85 Cr, which means the quarterly results carry a faster rise in bottom-line profit than in revenue.

Margin Improvement – Net profit margin improved to 12.6% from 10.4% in the comparison quarter. The outlook that follows picks up this results analysis.

FY27 Outlook After SMS Pharmaceuticals Q2 Results

The FY27 picture will be built quarter by quarter, and this results analysis of SMS Pharmaceuticals Q2 Results FY27 is one input. Full-year FY27 results will depend on subsequent quarters and disclosed sector conditions, with net profit of Rs 39.85 Cr as the base from which later quarters are compared.

Readers following the company can use the Univest Screener to view consolidated results, YoY growth and net profit trends for other listed companies, which helps place this quarter in context. Return on equity of 12.49% in FY26 is a reference point for how profit builds over a year. The risks that follow cover debt, returns and revenue swings.

Key Risks to Watch After SMS Pharmaceuticals Q2 Results FY27

Debt Level

Debt is high at 0.46 times total assets in FY26, and SMS Pharmaceuticals Q2 Results FY27 show that the YoY growth in revenue and profit sits alongside this balance sheet reading. Debt levels are the first risk to track.

Return on Equity

Return on equity of 12.49% in FY26 is below 15%, which means the company converted less equity into profit than that benchmark. The reading is worth tracking against coming quarterly filings.

Revenue Swings

Quarterly revenue has swung between Rs 206.97 Cr and Rs 316.09 Cr over the last 5 quarters. The latest quarter sits at the top of that range, so later filings will show whether the level holds.

Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.

Conclusion

SMS Pharmaceuticals Q2 Results FY27 combine revenue growth of 30.38% with a 57.45% rise in net profit, and the quarterly results are best read through the Operating Profit gain and the wider margin. The consolidated results for July to September 2026 give a clear base on the Univest Screener. Investors should consult a SEBI-registered advisor before acting on SMS Pharmaceuticals Q2 Results or any other filing.

Frequently Asked Questions on SMS Pharmaceuticals Q2 Results FY27

What are SMS Pharmaceuticals Q2 Results FY27?

Ans. SMS Pharmaceuticals Q2 Results FY27 are the quarterly results declared by SMS Pharmaceuticals on 4 November 2026, showing revenue of Rs 316.09 Cr. Alongside this, net profit was Rs 39.85 Cr, as set out in the Quick Answer box.

What is the results date for SMS Pharmaceuticals Q2 Results FY27?

Ans. SMS Pharmaceuticals declared the results on 4 November 2026, covering the July to September 2026 quarter. So the results date marks the Q2 FY27 declaration discussed in the opening paragraphs of this article.

What revenue was reported in SMS Pharmaceuticals Q2 Results FY27?

Ans. SMS Pharmaceuticals reported Consolidated revenue of Rs 316.09 Cr, compared with Rs 242.43 Cr a year earlier. Alongside this, the Financial Highlights table shows the same revenue figure with its YoY percentage.

What net profit was reported in SMS Pharmaceuticals Q2 Results FY27?

Ans. SMS Pharmaceuticals Q2 Results FY27 show net profit of Rs 39.85 Cr against Rs 25.31 Cr in the same quarter last year. Compared with the revenue rise, this net profit gain is analysed in the Performance Analysis section.

How much YoY growth did revenue show in SMS Pharmaceuticals Q2 Results FY27?

Ans. Revenue showed YoY growth of 30.38%, rising from Rs 242.43 Cr to Rs 316.09 Cr. This means revenue added Rs 73.66 Cr over the year, a gain detailed in the Performance Analysis section.

Did net profit rise or fall in SMS Pharmaceuticals Q2 Results?

Ans. In SMS Pharmaceuticals Q2 Results, net profit rose 57.45% YoY to Rs 39.85 Cr from Rs 25.31 Cr, while revenue grew 30.38%. Compared with that revenue gain, the profit rise is covered in the Performance Analysis section.

What was the Operating Profit in SMS Pharmaceuticals Q2 Results FY27?

Ans. Operating Profit was Rs 67.66 Cr, up 39.91% from Rs 48.36 Cr in the same quarter last year. Alongside this, the Key Takeaways section shows how this rise compares with revenue growth.

Are SMS Pharmaceuticals Q2 Results consolidated results or standalone results?

Ans. The reported figures are Consolidated results, not standalone results, for SMS Pharmaceuticals in the July to September 2026 quarter. This means every revenue and profit figure uses the consolidated basis shown in the Financial Highlights table.

What business factors shaped SMS Pharmaceuticals Q2 Results FY27?

Ans. Revenue growth of 30.4% YoY, a 57.4% net profit rise and a margin of 12.6% against 10.4% shaped the quarter. Alongside these, the Key Business Factors section sets out each driver in turn.

What are the key risks after SMS Pharmaceuticals Q2 Results FY27?

Ans. The key risks are debt at 0.46 times total assets in FY26, return on equity of 12.49% below 15%, and revenue swinging between Rs 206.97 Cr and Rs 316.09 Cr. These are explained in the Key Risks section.

What is the outlook after SMS Pharmaceuticals Q2 Results?

Ans. FY27 full-year results will depend on subsequent quarters and disclosed sector conditions, with net profit of Rs 39.85 Cr as the base for comparison. This means the FY27 Outlook section treats this quarter as one input, not a forecast.

Where can I find the complete SMS Pharmaceuticals Q2 Results FY27 data?

Ans. The complete SMS Pharmaceuticals Q2 Results FY27 data is in the Financial Highlights table, with related quarterly results for other listed companies on the Univest Screener and the Univest app. Alongside these, the Performance Analysis section explains the moves.